|Bid||186.10 x 800|
|Ask||186.17 x 900|
|Day's range||184.35 - 186.52|
|52-week range||142.81 - 223.04|
|PE ratio (TTM)||N/A|
|Earnings date||30 Oct 2018 - 5 Nov 2018|
|Forward dividend & yield||2.88 (1.52%)|
|1y target est||210.15|
In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
The US pharmaceutical sector is made up of players that include drug manufacturers, drug marketers, and biotechnology companies.
Allergan (AGN) presents positive results from a study, evaluating a higher dose of Botox for the treatment of glabellar lines.
U.S. health regulators say they'll convene a public meeting of medical advisers next year to discuss new science on breast implant safety, including an independent analysis that suggests certain rare health problems might be more common with silicone gel implants.
A look at the shareholders of Allergan plc (NYSE:AGN) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual toRead More...
On September 12, Allergan (AGN) announced the launch of Spotlyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. Spotlyte is an innovative digital hub designed to educate consumers about medical aesthetic treatments. The below chart lists key updates on Spotlyte. Spotlyte is the first venture from Project Moonwalker and is designed to educate consumers about medical aesthetics.
In August, the National Institutes of Health’s (or NIH) recombinant DNA advisory committee completed the NIH protocol for Editas Medicine’s (EDIT) EDIT-101. EDIT-101 is an investigational CRISPR genome editing therapy for the treatment of individuals with LCA10 (Leber Congenital Amaurosis type 10). Editas Medicine plans to submit an IND (Investigational New Drug) application to the FDA in October.
On September 6, Allergan (AGN) announced the launch of its new innovative dual-acting product, the SkinMedica Lumivive System. Lumivive is an innovative skincare product that works as a shield from blue light during the day and an essential skin repair process at night. The Lumivive System offers atmospheric protection during the day and fights the signs of aging for optimal skin health.
Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.
Glaukos’ (GKOS) share price rose ~40.3% and closed at $62.86 on August 29. The increase was a reaction to the news from Novartis’ (NVS) Alcon business unit about the immediate and voluntary withdrawal of its CyPass Micro-Stent across the world on June 29. In July 2016, the CyPass Micro-Stent was approved by the FDA to be used along with cataract surgery for patients suffering from mild-to-moderate primary open-angle glaucoma. The reduced competition for Glaukos’ glaucoma devices caused Robbie Marcus, a JPMorgan Chase analyst, to increase the company’s target price to $75, which implies an upside potential of ~19.3%—compared to the company’s last closing price.
Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.
AbbVie (ABBV) reports positive top-line results from a phase III extension trial on its investigational candidate Elagolix for treating uterine fibroids in women.
Retail stocks were a bright spot and rising oil prices drove energy names higher, as stock futures braced for the pending next round in the U.S.-China trade war.
Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.
FDA rejects Allergan's (AGN) new drug application for Esmya for the treatment of abnormal uterine bleeding in women with uterine fibroids, citing safety issues.
Analysts expect Allergan’s (AGN) adjusted EPS to be $16.29 on revenue of $15.53 billion in 2018, a 2.6% fall in revenue compared to $15.94 billion in 2017. Analysts expect the company’s adjusted net income to fall in 2018 mainly due to a fall in its gross profit margin and partially offset by a decrease in its selling, general, and administrative expenses as well as its research and development expenses. Allergan’s stock price has fallen nearly 20.2% over the last 12 months, but it’s risen ~12.8% year-to-date in 2018.
Allergan (AGN) is developing a variety of products through internal programs as well as in collaboration with other companies. A few of the products it currently has under development are Cenicriviroc, Atogepant, Bimatoprost SR, Ubrogepant, Abicipar, Rapastinel, and Sarecycline.
As we discussed earlier, Amgen (AMGN) reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017. Amgen surpassed analysts’ estimates for EPS and revenue in the second quarter, reporting non-GAAP (generally accepted accounting principles) EPS of $3.83 on revenue of ~$6.1 billion compared to the estimate of $3.54 on revenue of $5.7 billion.
Allergan’s (AGN) International Business segment includes the revenues from both its specialized therapeutics portfolio and its general products portfolio from outside US markets.
Allergan’s (AGN) US General Medicines segment includes women’s health products, central nervous system products, anti-infective products, gastrointestinal products, and diversified brands.
Allergan’s (AGN) US Specialized Therapeutics segment includes revenue from the US sales of specialized products, including eye care products, medical esthetics products, dermatology products, neuroscience products, and urology products.
As we discussed earlier, Allergan (AGN) has restructured its business over the last few years, and it now reports its revenues in three business segments.